



HENG FAI
BIOMEDICAL
GROUP PORTFOLIO



OVERVIEW

Heng Fai Biomedical



Heng Fai Biomedical



Global Research & Discovery Group





Heng Fai Biomedical



1

GLOBAL INFECTION
CONTROL CONSULTANTS



DAMAGE & COST OF INFECTIOUS DISEASES



Human



Veterinary



Agriculture




Environmental

SPANISH FLU PANDEMIC

(1918 – 1920)

GLOBAL MORTALITY RATES
in Millions



THE HIGH COST OF INFLUENZA

\$7.65b

appropriated by
Congress in June 2009
to fight pandemic flu
(including H1N1)

\$6.15b

spent and allocated
for vaccine purchases
and related supplies
(syringes, needles,
anti-virals and other
support)



THE HIGH COST OF INFLUENZA

Cost of school closures
due to influenza:

\$35 to

\$157

per student



THE HIGH COST OF INFLUENZA

Schools closures for
FOUR WEEKS
(consecutive) could lead
to a loss of

\$10b to

\$47b

in economic activity , or

0.1% to **0.3%** of

GDP



ESTIMATES OF NATIONAL PANDEMICS

- “MILD” pandemic that sickens 75 million and kills 100,000 people, akin to the 1957 and 1968 influenza outbreaks - 1 % drop in GDP
- “**MORE SEVERE**” scenario (on a scale of the 1918-19 Spanish influenza) that would infect 90 million and kill 2 million people - real GDP would be **4 to 4.5 percent lower.**

“ H1N1 virus could cause between 30,000 and 90,000 deaths in the United States this flu season. A typical seasonal flu kills between 30,000 and 40,000 each year. ”

*Advisory Group on Science and Technology
Obama administration*

“ More than one million Americans have been infected with H1N1, and around 20,000 have been hospitalized. At least 600 people in the U.S. died in 2009 ”

Center For Disease Control (CDC), USA



REUTERS VIDEO
The Latest in Business, Finance & Technology News

China's bird flu outbreak cost \$6.5 billion

BY **STEPHANIE NEBEHAY**

GENEVA | Tue May 21, 2013 5:14pm EDT

Tweet 105 Share 1 Share this 8+1 Email Print



TRENDING ON REUTERS

- 1 White House lockdown triggered by burning truck cleared
- 2 Protesters march in Wisconsin after black man shot dead by police
- 3 U.S., France 'on same page' over Iran, want stronger deal VIDEO
- 4 Iraqi troops battle to advance in towns on edge of Tikrit VIDEO
- 5 Snowden says he'd like to return to Geneva



/// The outbreak of Severe Acute Respiratory Syndrome (SARS) in 2003 is estimated to have caused over **\$50 billion-worth of damage to the global economy**, despite infecting only about 8,000 people and causing fewer than 800 deaths. That is because panic and confusion can be as disruptive as the disease itself. Studies of past outbreaks have shown that lethal diseases that lack a cure tend to provoke overreactions. This is true even if the risk of transmission is low, as is the case with Ebola. ///

The
Economist

The economic impact of Ebola

Panicking only makes it worse

Epidemics damage economies as well as health

Aug 16th 2014 | LAGOS AND LONDON | From the print edition



Comment (5)

Timekeeper reading list

E-mail

Reprints & permissions

Print

Advertisement



KNOWLEDGE & INSIGHTS CENTER

Explore
AIG's new
Knowledge
& Insights
Center.



NEWS BUSINESS

Home World Asia Australia India China UK **Business** Health Science Environment Technology Entertainment Video

Market Data Economy Entrepreneurship Business of Sport Companies Technology of Business Knowledge Economy

20 August 2014 Last updated at 23:03

Ebola crisis: The economic impact

By Richard Hamilton
BBC News



Military road blocks are preventing the movement of goods and workers

With more than 1,300 reported deaths from Ebola in West Africa, the virus continues to be an urgent health crisis, but it is also having a devastating impact on the economies of Guinea, Liberia and Sierra Leone.

"The economy has been deflated by 30% because of Ebola," Sierra Leone's Agriculture Minister Joseph Sam Sesay told the BBC.

Ebola outbreak

Ending Ebola
Survivor 'in hiding'
Why Ebola is dangerous

Top Stories



Boko Haram pledge to Islamic State

- Colombian rebels to help clear mines
- Malaysia remembers loss of MH370
- Obama hails Selma march 'heroes'
- IS 'demolishes' ancient Iraqi site

Features



A parent's right?
France refuses to be taught a lesson on smacking



The J-word
Being hated is part of being Jewish, argues Michael Goldfarb



A good walk
The artist who makes portraits with snowshoes



Weekend edition
The best reads of the past week that you may have missed

Shared **Read** Video/Audio

Top Gear presenter 'nearly died'



PRODUCTS & SERVICES

Path-Away[®]

ANTI-PATHOGENIC
SOLUTION



THE M3 SYSTEM[®]

MEASURE • MANAGE • MONITOR

PEOPLE ○



Arthur V. Martin

President

- Currently consulting across the United States and in over 16 foreign countries as of 1/1/2014.
- Trademark holder of an all natural anti-pathogenic tuberculocide and currently working with WHO and Departments of Chronic Disease Control, China and Thailand.
- Developed a trademarked system of pathogenic bioaerosol assessment for medical facilities for prophylactic air management of nosocomial infections.
- Developed a unique delivery system to infuse a natural based, drug and alcohol free anti-pathogenic product to 50+ AHUs simultaneously while monitoring numerous variable in real time.



AREAS OF CONCENTRATION



A. Medical

- Infection control



B. Agriculture

- Crop protection and enhancement
- Livestock and poultry protection and enhancement



C. The M3 System[®] Distribution Unit

- Automatic distribution system for Path-Away[®] solution in all buildings regardless of configuration or use.



Path-Away[®]

ANTI-PATHOGENIC
SOLUTIONS

- Product developed by GICC LLC USA and registered with USA Patent and Trademark Office **#4,032,774**.
- Certified Organic with no GMO
- Tested, proven and approved in numerous countries
- Efficacy against 120+ fungi, bacteria, yeasts and viruses including H1N1, Avian encephalitis, MRSA, C-diff, Mycobacterium tuberculosis and many more.
- Low enough toxicity that it can be used as a mouthwash.



Path-Away
Medical

SUCCESS PROJECTS



- Government Hospital in Riyadh, Saudi Arabia*
- King Fahd Medical City in Riyadh, Saudi Arabia*
- Houston Medical Clinic USA
- Mission Hospital, North Carolina USA
- Sheridan Dental Clinic
- Hospital Dialysis Center

** Each of these applications was done manually without benefit of The M3 System® Distribution Unit*



Path-Away

Agriculture

SUCCESS PROJECTS



- Efficacy against ***Pseudomonas syringae*** that was attacking the Kiwi fruit crop in New Zealand



- Efficacy against **Pineapple Wilt** cause by Mealy Bugs in the Philippines.



- Efficacy against **Cocolisap** currently affecting 60% of the Philippine coconut industry



Path-Away
Agriculture

SUCCESS PROJECTS

- On 24 November 2014, GICC LLC USA signed an agreement to collaborate with CNSC, Camarines Norte State College whereby **CNSC will act as the agent to supply and distribute Path-Away® Solution** as the product to remedy the PCA's (Philippine Coconut Authority) agricultural problem of their crops*
- CNSC will also conduct free research on other agricultural issues that GICC LLC USA brings to them


* This agreement **does not** extend outside of the Philippine territory.

M3 SYSTEM[®]



- Product developed by GICC LLC USA and registered with USA Patent and Trademark Office **#4,032,797**.
- Engineered to automatically **distribute Path-Away[®] Solution into buildings** on the basis of frequency and quantity necessary to **control airborne pathogens**.
- Prototype constructed and applied in a field application for evaluation.
- Redesigned for **simplicity, reliability** and **ease of installation** and operation but not in production.

M3 SYSTEM[®]



PREVENTION THROUGH INTERVENTION



- Chemical free
- Non-Toxic
- Biodegradable
- Alcohol-free
- Highest Efficacy
- Odor free
- Homeopathic
- Halal-Approved

M3 SYSTEM[®]

- Real time monitoring
- Temperature, Relative humidity, DP, CO, CO2
- Particulate monitoring
- Wi-Fi and Uncomplicated
- Up to 50 AHU's / System
- Flexible product delivery
- Global capability



H e n g F a i B i o m e d i c a l

FUNDING

Heng Fai Biomedical



GLOBAL
Infection Control Consultants LLC



CAPITAL REQUIREMENT

\$2 MILLION



USE OF FUNDS

- ▶ Development of M3 system
- ▶ Testing for Ebola (at University Biosecurity Level 4 Lab at University of Texas)
- ▶ FDA Approval and certification
- ▶ Development of China Market


** All currency reported as USD*

FUNDING

Heng Fai Biomedical



**PROJECTED
SALES**



* All currency reported as USD



Heng Fai Biomedical



2

LITE FOOD INC.




LITEFOOD INC.

AT A GLANCE

2013

Incorporated in the
United States



SHAREHOLDERS

74% **HOLISTA
COLLTECH**

26% *Private Investors*

“ To provide health-conscious solutions
to a comfort food loving world ”

OBJECTIVE

TARGET MARKET

U.S. is well known as the “Ground Zero” of the global **FAST FOOD INDUSTRY** in almost all aspects – business volume, regulatory, and innovation.

LITEFOOD INC.

PEOPLE



MR. JEFFREY BUSCH

President, Lite Food Inc.

- Graduated NYU School of Business with a BSc in Management, a Masters of Public Admin from NYU and a Doctor of Jurist Prudence from Emory University.
- Served as an Assistant to the United States Secretary of Housing and Urban Development
- Represented the United States at the United Nations in Geneva.
- Served as the President and Chief Executive Officer of Safe Blood International Foundation.
- Headed various Business enterprises since 1985.



DR. ROSCOE M. MOORE, JR.

Senior Adviser, Lite Food Inc.

- Graduated University of Michigan with a Masters of Public Health, both bachelor's and Doctor of Veterinary Medicine degrees from Tuskegee University, an honorary Doctor of Science in 1990 from Tuskegee University, and a Doctor of Epidemiology from Johns Hopkins University.
- Served as Assistant U.S. Surgeon General & Rear Admiral of U.S. Public Health Service
- Served as the Chief Epidemiologist with the Center for Devices and Radiological Health at the U.S. FDA.
- Served as the Senior Epidemiologist within the National Institute for Occupational Safety and Health, CDC

LITEFOOD INC.

PEOPLE



PROFESSOR HENRY, JEYAKUMAR

Scientific Adviser, Lite Food Inc.

- Graduated University of Bombay with a BSc (Tech) Food Technology, a Masters of Human Nutrition a Doctor of Human Nutrition from London School of Hygiene and Tropical Medicine. University of London.
- Served as part of the General Scientific Advisory Committee member, UK Food Standards Agency.
- Professor of Food & Human Nutrition at Oxford Brookes University (1997 – 2011)
- Currently serving as the Director of Clinical Nutritional Sciences, Singapore Institute of Clinical Sciences.
- One of the inventors of LITEFOOD INC.'s core innovations (three patents).

LITEFOOD INC.

RESEARCH & DEVELOPMENT

BEGINNINGS

Initial discovery and research began at the *Functional Food Center in Oxford Brookes University* (United Kingdom)

MARKET DRIVERS

Joint R&D at Switzerland with Veripan A.G.: the think-tanks of the European Bread Industry.

INCORPORATION

LITEFOOD INC.'s presence in the US provides the opportunity to be *represented in America* where most fast food chains are located.

GLOBAL DEVELOPMENT

LITEFOOD INC.'s innovation and development centers are a collaborative effort between researchers located in *Australia, Singapore, and Malaysia.*



LITEFOOD INC.

PARTNERSHIP



QUICK SERVICE RESTAURANT HOLDINGS

HOLISTA COLLTECH

BRANDS



EXCLUSIVE SUPPLY
AGREEMENT

2-year **geographic**
exclusivity in Australia

5-year **price** exclusivity

R&D & Commercial Collaboration



CORE INNOVATIONS

LITESALT SERIES

Sodium Reduction solutions

LITESALT²⁵™

Reduces the sodium content of table salt patented blend of natural emulsifier and starch by **25%** without affecting taste or mouthfeel outcomes in food applications.



LITESALT⁴⁰™

A prototype 1:1 salt replacement blend featuring a more aggressive **sodium reduction** (up to **40%**) is now available for evaluation.

CORE INNOVATIONS

GiLITE™

A proprietary blend of ingredients based on two common Asian foods meant for **reducing the Glycemic response** of carbohydrate-based foods by up to **40%**.



INTERNATIONAL TESTING CENTERS



THE UNIVERSITY OF
SYDNEY



CORE INNOVATIONS

GiLITE™

A proprietary blend of ingredients based on two common Asian foods meant for **reducing the Glycemic response** of carbohydrate-based foods by up to **40%**.



CURRENT STATUS

Bread Products: developed with **Veripan A.G.**



Market Penetration: major retail supermarket chains in Europe (Tesco UK and Migros Switzerland).

MIGROS

Currently in product evaluation and testing.



CORE INNOVATIONS

GiLITE™

A proprietary blend of ingredients based on two common Asian foods meant for **reducing the Glycemic response** of carbohydrate-based foods by up to **40%**.



CURRENT STATUS

Protocept products developed with **MATTSON**.

Marketing Concept: "55 Below Bakery offers a proprietary Lo-GI Flour that lowers the GI rating of baked goods and helps **balance blood sugar levels** so you feel full and satisfied longer."



CORE INNOVATIONS

LITESUGAR SERIES

Low Calorie sweetening solutions

80LESS™

80LESS is **5x sweeter than sugar** resulting in **80% fewer calories from sugar**. 80LESS is specifically designed and processed for use with liquid and dry mix applications, and can replace sugar's major role in maintaining the sweetness profile of natural sugar and recipe characteristics.

CURRENT STATUS

Product Development Interest
By **Starbucks Coffee Company**.

Currently in R&D stages.



CORE INNOVATIONS

LITESUGAR SERIES

Low Calorie sweetening solutions

ZEROVIA™

A proprietary blend of stevia and sucrose that can be used as a sugar substitute in virtually any application (except as a bulking agent). This zero calorie sweetener has no after-taste, and can be used in cooking. **Just one teaspoon replaces two teaspoons of sugar.**

PRODUCT FEATURES

- Reduces **oil uptake** in deep fat fried foods.
- FDA-compliant **natural** ingredients.
- Patent-pending **dual-stage wash system**.
- **No change** in sensory characteristics (taste, texture, and appearance) in final treated fried-food products.



CASE STUDIES

1

UNIVERSITY OF WESTERN AUSTRALIA

2012

NATURE OF STUDY

- Scope: Laboratory Investigation

FOOD PRODUCT

- Deep fried potato chips (French fries)

METHOD OUTLINE

- Chips cut from same potato – divided into 2 groups.
- Group 1 (*treatment*) received the two-stage patented process.
- Group 2 (*control*) received the two-stage process but with plain water only.
- Both groups fried side-by-side (time = 2.45 minutes)

CASE STUDIES

UNIVERSITY OF WESTERN AUSTRALIA

RESULTS HIGHLIGHT

A	T	5.3925	74.3010	74.8770	0.5760	10.68%	39%
	U	5.0576	74.6240	75.5140	0.8900	17.60%	
B	T	6.8761	73.8540	74.5570	0.7030	10.22%	56%
	U	6.2027	71.9750	73.4200	1.4450	23.30%	
C	T	5.6273	74.1100	74.8140	0.7040	12.51%	59%
	U	5.2296	71.7600	73.3460	1.5860	30.33%	
D	T	4.649	74.6150	74.7700	0.1550	3.33%	49%
	U	5.3749	72.0660	72.4200	0.3540	6.59%	
E	T	4.4284	74.3970	74.5550	0.1580	3.57%	30%
	U	5.0932	74.2110	74.4690	0.2580	5.07%	
F	T	5.2323	74.6420	75.0420	0.4000	7.64%	43%
	U	5.1721	71.9270	72.6210	0.6940	13.42%	
G	T	5.9928	74.3310	74.8430	0.5120	8.54%	34%
	U	5.0978	74.1190	74.7770	0.6580	12.91%	



**CASE
STUDIES**

UNIVERSITY OF WESTERN AUSTRALIA

RESULTS HIGHLIGHT

1



After the oils were extracted, the **neusolite** fries contained up to **60% less fat.**

CASE STUDIES

2

RUTGERS FOOD INNOVATION CENTER

2014


NATURE OF STUDY

- Scope: Pilot Plant Simulation

FOOD PRODUCT

- Deep fried potato chips (French fries); Russet Burbank potatoes

METHOD OUTLINE

- Study objective(s): to determine if  could be applied to an *industrial context* of French Fries manufacturing.
- Trial performed using process emulating known industrial production lines (proprietary; adapted from Simplot & McCain lines).

CASE STUDIES

RUTGERS FOOD INNOVATION CENTER

REQUIREMENTS

2

Target industrial fat reduction:
-25% OR LOWER
fat content compared to standard
recipe.

CASE STUDIES

RUTGERS FOOD INNOVATION CENTER

RESULTS HIGHLIGHT

Percent Fat Analysis Results : From Rutgers Test Run August 2014 (F= Fan Cooled 2:30 seconds)

Batch Test	Control Composite - Soxhlet	Control Composite -F- Soxhlet	1-Composite-F (Soxhlet)	2-Composite-F (Soxhlet)	3-Composite-F (Soxhlet)	4-Composite-F (Soxhlet)
Mean (%)	18.46	16.98	12.35	11.82	12.51	11.94
%Change			27.3%	30.4%	26.3%	29.7%



...[Neusolite] does reduce the absorption of fat without having sensory or color perceivable differences from standard French fries locally available...



Rutgers Neusolite Test Production Report



CASE
STUDIES

RUTGERS FOOD INNOVATION CENTER

RESULTS HIGHLIGHT

2

25%

AND BEYOND

A **25% or GREATER** fat
reduction

In **neusolite** treated
fries was successfully
achieved when
compared to the
control.

CASE STUDIES

AGRISTO, TILBERG (THE NETHERLANDS)

ONGOING


NATURE OF STUDY

- Scope: Full Scale Production Testing

FOOD PRODUCT

- Deep fried potato chips (French fries)

METHOD OUTLINE

- Study objective(s): to determine if neusolite could be applied to a continuous industrial process (**1000 ton-scale**).
- Trial would evaluate :
 - Fat reduction **consistency**;
 - **Oil consumption reduction** during frying;
 - **Minimal retrofitting** to existing process.

3

CASE
STUDIES

AGRISTO, TILBERG (THE NETHERLANDS)

ONGOING

RESULTS OUTCOME

3



Launch in the E.U. with leading potato products supplier.

CASE STUDIES

AVIKO B.V., (THE NETHERLANDS)

PROSPECTIVE

COMPANY PROFILE

- AVIKO B.V. is the number 1 Europe-Based potato processor.

SCOPE OF WORK

- Potato Products (Fries, Specialty, Pre-Cooked)

IN PIPELINE

- Joint R&D aimed at fat reduction of AVIKO house brand potato products to be launched in the Netherlands.

4

CASE STUDIES

NEWLY WEDS[®] FOODS

PROSPECTIVE

COMPANY PROFILE

- Newly Weds is the premier global purveyor of customized breading, batters, seasonings, and functional ingredients.

SCOPE OF WORK

- Breaded Fried Foods (Fritters, Tempura, Nuggets etc.)

IN PIPELINE

- Joint R&D aimed at fat reduction in battered fried food products for retail and quick service restaurants

5

Lite Foods



FUNDING

Heng Fai Biomedical



Lite Foods



CAPITAL REQUIREMENT

\$1 MILLION



USE OF FUNDS

- ▶ Completion of Neusolite™ fat reduction trials.
- ▶ Development of low GI product with Mattson (55 Below Bakery)
- ▶ Marketing (Global)


** All currency reported as USD*

FUNDING

Heng Fai Biomedical



**PROJECTED
SALES**



* All currency reported as USD



Heng Fai Biomedical



3

GLOBAL RESEARCH
& DISCOVERY GROUP



Global Research & Discovery Group



Global Research & Discovery Group

COMPANY OVERVIEW

VISION

To create a healthier world by **offering a solution to dementia and AD**, one of the mass metabolic disorders identified by the inventors, recently termed **Type III Diabetes**

To develop a **non-toxic medical food**, which will both treat and prevent Alzheimer's Disease by affecting currently un-researched metabolic pathways. By bringing in such compounds from outside their organizations, drug and medical food companies are expected to save significant development costs and shorten the time to market.



MISSION



STAGE

Final Validation
Utah University



INDUSTRY

BIOTECHNOLOGY

LOCATION

Winter Haven,
Florida, USA



YEAR
2010

FOUNDED



GLOBAL RESEARCH & DISCOVERY GROUP

WHO WE ARE



PEOPLE

Thompson and Ahrens jointly hold several patents and IP, from medical devices, to retroviral agents (SARS, MERS), to therapeutics for the treatment of diabetes and Alzheimer's Disease and other metabolic disorders.



Daryl L. Thompson

Biochemist; President and Director of Research.

Serial inventor and entrepreneur. Specializing in computer modeling and simulations, and computer assisted drug design.



M. Joseph Ahrens.

Physiologist; COO and Director of Scientific Affairs.

Specializing in project and laboratory management. Former faculty, Univ. of California Davis.



GLOBAL RESEARCH & DISCOVERY GROUP

WHO WE ARE

- ▶ GRDG was formed to commercialize the Intellectual Property of biochemist **Daryl Thompson** and physiologist **Joe Ahrens**.
- ▶ GRDG is a private research and development organization that applies rapid analysis and problem solving skills to quickly qualify, quantify, procure and test both applicable and accurate paradigms.
- ▶ GRDG endeavors to be the world's leading think tank and troubleshooting research organization that can **outperform government and university institutions** by **minimizing bureaucracy** and maximizing real "on-the ground" problem solving capabilities.



GLOBAL RESEARCH & DISCOVERY GROUP

WHO WE ARE



KEY ADVISORS

- **MICHAEL NOVINSKI**, past CEO or SVP of Organon Pharmaceuticals, Wyeth International, Emisphere Technologies,
- **CORY ZWERLING**, past president of Bristol Myers Squibb.
- **DR. GARY STROBEL**, Professor of Plant Physiology, Montana State Univ., discoverer of endophytic taxol, and holding over 20 drug-related patents.
- **DR. DAVID SINCLAIR**, Professor of Pathology, Harvard Medical School, discoverer of resveratrol, the anti-aging, anti-cancer component of red wine.



INTELLECTUAL PROPERTY

- ▶ GRDG is an active, rapid, drug discovery research team whose technologies are often “disruptive” to established institutional thought.



GLOBAL RESEARCH & DISCOVERY GROUP



INTELLECTUAL PROPERTY

- ▶ **This has led to a series of new and successful products and patents for:**
 - therapeutics for the treatment of type 1 & 2 diabetes.
 - a therapeutic for the treatment of Alzheimer's Disease.
 - an orally administered prophylactic for sunburn.
 - a treatment and prophylactic for gamma and UV radiation exposure.
 - a therapeutic for the treatment of migraine headaches.
 - a "super aspirin"
 - retroviral and antiviral agents for SARS, MERS.
 - therapeutics for the treatment of Parkinson's, Huntington's
 - an anti-viral agent for the treatment of H1N1.
 - a therapeutic for the treatment of Irritable Bowel Syndrome.



MEDICAL FOOD

THE FUTURE


“ ...A food which is formulated to be consumed or administered internally under the supervision of a physician and which is intended for **the specific dietary management of a disease or condition** for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation... ”

Section 5(b) of the Orphan Drug Act (21 U.S.C. 360ee (b) (3))



ALZHEIMER'S vs. OTHER NON- COMMUNICABLE DISEASES

“...Whoever takes the first **Alzheimer's** blocking therapeutic to market stands to make **billions** of dollars...” ”





UNDERSTANDING ALZHEIMER'S

Alzheimer's Disease (AD) not only affects the person with the disease, but also the family member(s) who becomes the primary caregiver(s), a demanding and stressful duty.

Some may receive institutional care, at a huge cost to society.



Slow death of brain cells

Dementia characterized by memory loss, impaired judgment, and behavioral changes including aggression



Eventual loss of speech, bladder and bowel control

Death from infections or other medical problems 7 to 20 years after diagnosis.





UNDERSTANDING ALZHEIMER'S COST AND DAMAGE

- AD is the 6th leading cause of death in the US, surpassing diabetes
(Center For Disease Control, 2008)
- 10 million baby boomers to suffer
- The Alzheimer's Association reports **there is no current cure**



More than
\$148b
each year

Direct and indirect costs of AD and other dementias to medicare, medicaid and businesses.



AD Mortality
45%
increase

Largest % change (increase of 45%) in Leading Causes of Death 2000 to 2005, while heart disease, cancer and stroke have all diminished.



UNDERSTANDING ALZHEIMER'S MARKET INSIGHT

- AD market to be USD 4.5 Billion annually.
- 5 million Americans sufferers.
- New amyloid plaque-dissolving drug, was to be launched in 2011 (called AAB-001) will be worth \$10 billion annually by 2015 and \$14 Billion by 2017
- This would be the closest drug to **Neuroptin** for a current comparison.



UNDERSTANDING ALZHEIMER'S DIABETES OF THE BRAIN

“...**Insulin abnormalities** have been implicated in neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's. Among the latest findings is the discovery that a gene linked to insulin processing is located in a chromosomal area linked to Parkinson's... “That made it clear that one can get exactly the same problems as in regular diabetes except confined to the brain,” says de la Monte, who refers to Alzheimer's as **“Type 3 diabetes.”**... ”



GRDG DISCOVERY

NEUROPTIN:
A NEW HOPE FOR
AD SUFFERERS

- We are successful metabolic researchers and have **discovered the underlying cause and treatment** for Alzheimer's Disease
- Patents and Patents Pending
- Pre-clinical tests and modeling/simulations have been successful



Seeking *\$4 million* total to **finish human clinical and related research**



In **24 to 30 months** the therapeutic will be *ready to market* as a Medical Food




GRDG DISCOVERY

NEUROPTIN:
A NEW HOPE FOR
AD SUFFERERS



PRE-CLINICAL SUCCESS

▶ Effects of Test Articles on Amyloid- β Aggregation in AD Model Transgenic Mice.



F = treated with Neuroptin



Global Research & Discovery Group

GRDG DISCOVERY

NEUROPTIN:
A NEW HOPE FOR
AD SUFFERERS



PRE-CLINICAL SUCCESS

From: Betty S.

Sent: Thursday, June 26, 2014 10:20 PM

To: Russ W

Subject: Don

We had one fantastic day today! Don woke up this morning and started talking again!!!! We are so excited.

Big Hugs and Much Love, Betty



GRDG DISCOVERY

NEUROPTIN:
A NEW HOPE FOR
AD SUFFERERS



PRE-CLINICAL SUCCESS

Dr. Ahrens,

I cannot tell you how you have changed my life. As you know, previous to meeting your company through a Boston Red Sox colleague, I had lost the ability to speak coherently and my mind, for lack of a better word, was cloudy and I had become somewhat of a recluse. I am now so fluid that I have spoken at Boston Red Sox Retired Professional Players Association events. What a change, and so quickly.

Gerald Moses.



Global Research & Discovery Group

GRDG DISCOVERY

NEUROPTIN:
A NEW HOPE FOR
AD SUFFERERS



PRE-CLINICAL SUCCESS

Dear Dr. Ahrens,

We are blessed to be able to participate in this trial. After being identified as stage 2 Alzheimer's, we had lost hope for my father. But since, he has shown no further development of dementia and in fact has become almost completely normal.

Thank you,

Cate P.



GRDG DISCOVERY NEUROPTIN: A NEW HOPE FOR AD SUFFERERS

WHY WE ARE CONFIDENT

- ▶ Outstanding technical and biochemical skills
 - Unique insight and integrated approaches to biological systems unavailable in other research organizations.
 - Dr. Ralph DeFronzo, leading metabolic researcher, stated “GRDG is 10 years ahead of anyone in their field.”
 - Dr. David Sinclair, Harvard Professor and discoverer of resveratrol, stated “GRDG is light years ahead in understanding these metabolic processes.”
 - Past discoveries have been termed “true breakthroughs”



PARTNERSHIP



Global Research & Discovery Group

GRDG DISCOVERY
NEUROPTIN:
A NEW HOPE FOR
AD SUFFERERS

WHY WE ARE CONFIDENT

- ▶ Outstanding project management and implementation experience.
 - Over 35 years of project design, implementation, and management including oversight of major laboratories and research facilities at private and public institutions with budgets between \$5000 and \$34 million.



PARTNERSHIP



GRDG DISCOVERY
NEUROPTIN:
A NEW HOPE FOR
AD SUFFERERS

WHY WE ARE CONFIDENT

► Risk Management

RISK	MITIGATION
Cost Overruns	Using CROs with Known Contracted Costs
Excessive Overhead	Low Overhead using CROs
Therapeutic will not Work	Computers Predict Success
	Previous Success in Diabetes with Same System Success in Pre-clinical Humans
IP Protection	Have Engaged the Top Level Attorneys
	No current Conflicting IP
	Secure Systems
Continuity	Key Man Insurance



PARTNERSHIP



Global Research & Discovery Group

GRDG DISCOVERY
NEUROPTIN:
A NEW HOPE FOR
AD SUFFERERS

WHY WE WILL BE SUCCESSFUL



▶ The Team

- Ahrens and Thompson have been working together 12 years and exactly complement each other for the perfect team.



PARTNERSHIP



GRDG DISCOVERY NEUROPTIN: A NEW HOPE FOR AD SUFFERERS

WHY WE WILL BE SUCCESSFUL



▶ History

- Have successfully patented and introduced several therapeutics for metabolic diseases such as diabetes, Parkinson's, cardiovascular, inflammatory, and pain.
- In negotiations with major pharmaceutical companies for licensing of above.
- Previous related work, using the same discovery process and Computer Assisted Drug Discovery, predicts 98% success.



PARTNERSHIP



Global Research & Discovery Group



H e n g F a i B i o m e d i c a l

FUNDING

Heng Fai Biomedical



Global Research & Discovery Group



CAPITAL REQUIREMENT

\$4 MILLION



USE OF FUNDS

- ▶ Clinical validation (Neuroptin) duration : 24 – 30 months
- ▶ \$2.0m - Primary & Secondary human clinical validation trials
- ▶ \$0.3m - Raising transgenic rodents
- ▶ \$0.3m - In-house research
- ▶ \$0.3m - Legal fees, registration and related services
- ▶ \$0.2m - Facilities and related equipment
- ▶ \$0.2m - Administration and support
- ▶ \$0.7m - Contingency provision

* All currency reported as USD

FUNDING


Heng Fai Biomedical



Global Research & Discovery Group



PROJECTED SALES



* All currency reported as USD



Heng Fai Biomedical



4

iGALEN



VISION

TO LIVE IN A WORLD OF
MINIMIZED AND MANAGED
INFLAMMATION,
LEADING TO *IMPROVED*
HEALTH AND *PROLONGED*
USEFUL LIFE.

MISSION

**TO EDUCATE PEOPLE
ON THE DANGERS OF
INFLAMMATION
AND PROVIDE THE
NATURAL SCIENTIFICALLY
TESTED SOLUTIONS AND
LIFESTYLE OPTIONS.**

ABOUT US



CONN FLANIGAN

Director, iGALEN USA

- ▶ B.A. in international Relations (University of San Diego); Juris Doctor Degree (University of Denver Sturm College of Law)
- ▶ Served as General Counsel and Secretary with several U.S. Subsidiaries of Heng Fai Enterprises Ltd. Began advising these subsidiaries as in house Corporate Counsel in 2000 and was appointed to General Counsel in 2007
- ▶ Advises on all corporate and securities matters, including corporate finance and structure, debt, and equity offerings, and securities compliance. He also negotiates, drafts, and oversees and companies' transactions.

ABOUT US



CHAN HENG FAI

Advisor, iGALEN

- ▶ Director of Holista Colltech Limited.
- ▶ Entrepreneur with a global footprint.
- ▶ Skilled at restructuring and financial engineering
- ▶ Turned around the ailing American Pacific Bank. and resold it to the Federal Reserve.
- ▶ Sees potential in healthcare nutritional products.
- ▶ Big believer in Network Marketing concept to deliver quality unique healthcare products globally.

ABOUT US



RAJEN M, PhD

Scientific Advisor, iGALEN

- ▶ Executive Chairman and CEO of Holista CollTech Limited.
- ▶ Pharmacist with Doctorate in Holistic Medicine. Specializes on effects of carbohydrates on human metabolism.
- ▶ Founder of the Holista Group of Companies.
- ▶ Authored the National Natural Products Blueprint for Malaysia.
- ▶ Actively engaged in the field of Holistic Medicine and R&D of Functional Natural Products.
- ▶ Formerly Health Columnist (The Star, The Edge, New Straits Times)
- ▶ Mission is to build an ethical network marketing company.

ABOUT US

HOW IS iGALEN DIFFERENT

- ▶ Science based
- ▶ Backed by an Australian public listed company
- ▶ Dedication to ethical values
- ▶ Long-term view
- ▶ End-consumer in mind in all that we do

PARTNERS



EXCLUSIVE
SUPPLY

HOLISTA
COLLTECH



FUTURE
OFFERINGS

RESEARCH &
DEVELOPMENT

PARTNERS

PARTNERS

HOLISTA COLLTECH

The Australian world leader in sheep collagen research, development and manufacture. Holista also focuses on functional food ingredients.

(www.holistaco.com)



Working with an extensive global network of universities, medical centres, and laboratories, the company develops cutting edge products in natural health care. It produces the most advanced form of free curcumin.

(www.vs-corp.com)



Global Research & Discovery Group

Global research and Discovery Group, LLC aims to be the world's think-tank and troubleshooting research organization that can outperform government an university institution by minimizing beraeucracy and maximizing real "on the ground" problem solving capabilities.

(www.globalrdg.com)

PARTNERS



A 40 year-old South Korean world leader in Ginseng science and an Award winner of Engredea – Best Botanical 2012

(www.ilhwakoreanginseng.com)



palmabiotech

Designs and develops innovative high-quality actives based on profound scientific knowhow of powerful encapsulation technology that guarantees optimum bioavailability. This Spanish company is a world leader with liposome encapsulation.

(fod85.wix.com/palmabiotech)



The company is firmly focused on returning the origins of drug discovery by exploring the metabolic and physiological pathways of plants. The company's breakthrough technology lead to the development of the World's First Carbohydrate Manager- Emulin™

(www.atmmetabolics.com)

ORIGINS

“ ...inflammation can be defined as swelling, redness, heat and pain. If allowed to go on, it can lead to loss of organ and body function...”

CLAUDIUS GALEN 129 – 216 AD



CLAUDIUS GALEN

(GALEN OF PERGAMON)

- ▶ Prominent Greek physician, surgeon and philosopher.
- ▶ Physician to several Roman Emperors of his time
- ▶ Influenced the development of various scientific disciplines. (anatomy, physiology, pathology, pharmacology, etc.)

ORIGINS

Most noted contribution:
**INFLAMMATION
IS THE ROOT OF
NEARLY ALL
SICKNESSES**

*Galen was the
Physician to
several
Roman
Emperors*



*Considered by many
as 'The Father of
Modern Medicine'*



GALENICAL

(as opposed to
Pharmaceutical) means
“a medicinal preparation
concocted mostly out of
herbs or vegetal matter”,
is named **in honor of
Galen.**

*Employed more
than 20 writers
to document his
findings in the
tune of 10
million words*

*The most advanced
works in medicine
since Hippocrates*

ORIGINS

- ▶ CANCER
- ▶ CARDIOVASCULAR DISEASE
- ▶ ALZHEIMER'S DISEASE
- ▶ PULMONARY DISEASE

CHRONIC INFLAMMATION

- ARTHRITIS ◀
- AUTOIMMUNE DISEASES ◀
- NEUROLOGICAL DISEASES ◀
- DIABETES ◀

PRODUCTS

CARBOHYDRATE
MANAGEMENT

HIGHLY
BIOAVAILABLE
GINSENG



SHEEP
COLLAGEN



HIGHLY
BIOAVAILABLE
TURMERIC



PRODUCTS



DeCARBTM

The World's 1st
Complete Carbohydrate
Management System



PRODUCTS




the story of DeCARB™

DeCARB™ is an all natural patented compound derived from parts of plants

- ▶ Dr. Ahrens and Dr. Thompson identified three phytochemicals that emulated insulin (hence the name **EMULIN™**) at various key enzymatic control points and increase insulin sensitivity.
- ▶ These compounds have been left out in our modern day diets as we processed and refined our food.

benefits of EMULIN™

- ▶ The three actives of **EMULIN™** work in synergy to protect the body's ability to manage the ill effects of consuming excess carbohydrates at the known and **established 7 carbohydrate metabolic points**.
- ▶ **EMULIN™** was developed after years of research using sophisticated 3D computer modelling which tested against huge databases of enzymes and natural compounds known to exist in nature.



PRODUCTS

the creators of **EMULIN™**

- ▶ **EMULIN™** was invented by Daryl Thompson, a food and biochemist, and Dr. Joseph Ahrens, former director of research for the Florida Citrus Board, by studying the use of grapefruit in weight loss and improving other metabolic outcomes like control of blood sugar and blood fats.
- ▶ Dr. Ahrens and Dr. Thompson then started working on why grapefruit helps with weight loss and improvement of blood sugar and blood fats.




Inventors of **EMULIN™** Dr. Thompson (left), Dr. Ahrens (right)

PRODUCTS




the creators of EMULIN™

- ▶ That resulted in “The Grapefruit Solution™” book that proved to be a huge success in the United States.
- ▶ However, they went beyond the grapefruit and discovered unique compounds in plants – vegetables, fruits, and spices – that helps the body protect itself from excess carbohydrate intakes.
- ▶ The resulted in the creation of EMULIN™ and its subsequent patent by its inventors.



PRODUCTS

Change In 2 Hr Postprandial Glucose



PRODUCTS

“ ...I have never seen anything perform like this in this severe of a model, other than insulin itself...you may be **regenerating β -cells**...”



Dr. Gary Grover, Principle Investigator, Director
Product Safety Laboratories

PRODUCTS

the future offerings of iGalen



LONGVIDA®

Anti-Inflammatory

- ▶ Powered by a patented (EP 1993365) SLCP™ Technology (Solid Lipid Curcumin Particles)
- ▶ Co-developed by the University of California in Los Angeles (UCLA).
- ▶ **LONGVIDA®** Optimised Curcumin delivers free-curcumin into target tissues through the critical bioavailability requirements of permeability, solubility, and stability.
- ▶ Allows high-levels of free curcumin to be present in all organ tissues, the joints, and even the brain.

PRODUCTS

the future offerings of iGalen



GS15-4[®]

21st Century “Pre-Digested” Ginseng

- ▶ Koren technology clinically proven to provide 15 times increased absorption, 4 times faster absorption, and 4 times more consistent absorption.
- ▶ Process provides improved taste profile compared to conventional ginseng extracts.
- ▶ Improved bioavailability means improved adaptogenic support for fatigue, stress, and increased energy.
- ▶ The “Pre-Digested” process is backed by 4 patents and proprietary technology.



H e n g F a i B i o m e d i c a l

FUNDING

Heng Fai Biomedical



iGALEN
MANAGING INFLAMMATION NATURALLY



CAPITAL REQUIREMENT

\$2 MILLION



USE OF FUNDS

- ▶ Fast track launches in USA, Australia, Indonesia, Philippines, Singapore, Hong Kong.
- ▶ Online launch into China.
- ▶ Building online presence.

** All currency reported as USD*

FUNDING


Heng Fai Biomedical



iGALEN
MANAGING INFLAMMATION NATURALLY



**PROJECTED
SALES**



* All currency reported as USD



Heng Fai Biomedical



SUMMARY

CAPITAL REQUIREMENT

Heng Fai Biomedical



USD 2.0
MILLION



PROJECTED SALES

USD 11.5
MILLION

ON YEAR 5




USD 1.0
MILLION



PROJECTED SALES

USD 6.0
MILLION

ON YEAR 5



Global Research & Discovery Group



USD 4.0
MILLION



PROJECTED SALES

USD 7.0
MILLION

ON YEAR 5



USD 2.0
MILLION



PROJECTED SALES

USD 5.0
MILLION

ON YEAR 4

FUNDING

Heng Fai Biomedical



GLOBAL
Infection Control Consultants LLC



CAPITAL REQUIREMENT
\$2 MILLION



USE OF FUNDS

- ▶ Development of M3 system
- ▶ Testing for Ebola (at University Biosecurity Level 4 Lab at University of Texas)
- ▶ FDA Approval and certification
- ▶ Development of China Market


** All currency reported as USD*

FUNDING

Heng Fai Biomedical



**PROJECTED
SALES**



* All currency reported as USD

FUNDING

Heng Fai Biomedical



Lite Foods



CAPITAL REQUIREMENT
\$1 MILLION



USE OF FUNDS

- ▶ Completion of Neusolite™ fat reduction trials.
- ▶ Development of low GI product with Mattson (55 Below Bakery)
- ▶ Marketing (Global)


** All currency reported as USD*

FUNDING

Heng Fai Biomedical



**PROJECTED
SALES**



* All currency reported as USD

FUNDING

Heng Fai Biomedical



Global Research & Discovery Group



CAPITAL REQUIREMENT

\$4 MILLION



USE OF FUNDS

- ▶ Clinical validation (Neuroptin) duration : 24 – 30 months
- ▶ \$2.0m - Primary & Secondary human clinical validation trials
- ▶ \$0.3m - Raising transgenic rodents
- ▶ \$0.3m - In-house research
- ▶ \$0.3m - Legal fees, registration and related services
- ▶ \$0.2m - Facilities and related equipment
- ▶ \$0.2m - Administration and support
- ▶ \$0.7m - Contingency provision

** All currency reported as USD*

FUNDING


Heng Fai Biomedical



Global Research & Discovery Group



**PROJECTED
SALES**



* All currency reported as USD

FUNDING

Heng Fai Biomedical



iGALEN
MANAGING INFLAMMATION NATURALLY



CAPITAL REQUIREMENT

\$2 MILLION



USE OF FUNDS

- ▶ Fast track launches in USA, Australia, Indonesia, Philippines, Singapore, Hong Kong.
- ▶ Online launch into China.
- ▶ Building online presence.

** All currency reported as USD*

FUNDING


Heng Fai Biomedical



iGALEN
MANAGING INFLAMMATION NATURALLY



**PROJECTED
SALES**



** All currency reported as USD*



THANK YOU



HENG FAI
BIOMEDICAL
GROUP PORTFOLIO

